Ependymomas of the adult: Molecular biology and treatment

Current Opinion in Neurology

Volumn 21, Issue 6, 2008, Pages 754-761

  Rudà, Roberta ^a   Gilbert, Mark ^b   Soffietti, Riccardo ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ependymomas; Molecular biology; Prognostic factors; Treatment

Indexed keywords

CARBOPLATIN; DIAZIQUONE; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; ISOTRETINOIN; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; TUMOR MARKER;

ANAPLASTIC CARCINOMA; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CHROMOSOME ABERRATION; CLINICAL TRIAL; EPENDYMOMA; EPIGENETICS; GENE EXPRESSION PROFILING; HUMAN; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PATHOLOGICAL ANATOMY; PROGNOSIS; RADIODIAGNOSIS; REOPERATION; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EPENDYMOMA; HUMANS; MOLECULAR BIOLOGY;

EID: 56749109572     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328317efe8     Document Type: Review

References (106)

1. Chamberlain MC. Ependymomas. Curr Neurol Neurosci Rep 2003; 3:193-199.
2. Tseng JH, Tseng MY. Survival analysis of 459 adult patients with primary spinal cancer in England and Wales: a population-based study. Surg Neurol 2007; 67:53-58. The first nationwide population-based study on adult patients with spinal cancer.
3. Henson JW. Spinal cord gliomas. Curr Opin Neurol 2001; 14:679-682.
4. Reni M, Gatta G, Mazza E, et al. Ependymoma. Crit Rev Oncol Hematol 2007; 63:81-89. A thorough review of ependymomas of the adult.
5. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9:157-173.
6. Rossi A, Caracciolo V, Russo G, et al. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 2008; 14:971-976.
7. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999; 155:627-632.
8. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001; 91:803-808.
9. Scheil S, Bruderlein S, Eicker M, et al. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 2001; 11:133-143.
10. Jeuken JW, Sprenger SH, Gilhuis J, et al. Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002; 197:238-244.
11. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006; 24:5223-5233.
12. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001; 58:1137-1143.
13. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridization in paediatric ependymoma. Genes Chromosomes Cancer 2001; 32:59-66.
14. Carter M, Nicholson J, Ross R, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridization. Br J Cancer 2002; 86:929-939.
15. Mendryzk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12:2070-2079.
16. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002; 8:3054-3064.
17. Lim M, Guccione S, Haddix T, et al. Alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol 2005; 36:665-669.
18. Roma AA, Prayson RA. Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology 2006; 26:422-428.
19. De Bont JM, den Boer ML, Kros JM, et al. Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteomewide analysis. J Neuropathol Exp Neurol 2007; 66:505-516. A study identifying some tumor-specific proteins in pediatric primitive neuroectodermal tumors and ependymomas.
20. De Bustos C, Smits A, Stromberg B, et al. A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. J Med Genet 2005; 42:31-37.
21. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163:1721-1727.
22. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005; 7:20-31.
23. Lukashova-v Zangen I, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007; 113:325-337. A study investigating the relationship between gene expression profile and proliferation index, histologic subtype, location and outcome in pediatric and adult ependymomas.
24. Waha A, Koch A, Hartmann W, et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 2004; 110:542-549.
25. Hamilton DW, Lusher ME, Lindsey JC, et al. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 2005; 227:75-81.
26. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006; 166:74-81.
27. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8:323-335.
28. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer 2007; 96:6-10. A thorough review of current knowledge on the role of stem cells in ependymomas.
29. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
30. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12:328-331.
31. Kulkarni AV, Drake JR. Intracranial ependymomas. Brain tumors. In: Kaye AH, Laws ER, editors. London: Churchill Livingstone, pp. 541-550.
32. Kawabata Y, Takahashi JA, Arakawa Y, et al. Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 2005; 103:31-37.
33. Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61:387-391.
34. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005; 75:287-299.
35. Goldwein JW, Sutton LM. Ependymomas. In: Black PM, Loeffler JS, editors. Cancer of the nervous system. Philadelphia: Lippincot Williams & Wilkins; 2005. pp. 533-542.
36. Guyotat J, Signorelli F, Desme S, et al. Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol 2002; 60:255-268.
37. Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004; 100:1221-1229.
38. Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130:1338-1349. The largest multiinstitutional retrospective analysis of intracranial ependymomas in adult patients, based on central pathology review.
39. Schiffer D, Chio A, Cravioto H, et al. Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery 1991; 29:206-210.
40. McLaughlin MP, Marcus RB Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40:845-850.
41. Korshunov A, Golanov A, Sycheva R, et al. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004; 100:1230-1237.
42. Wolfsberger S, Fischer I, Höftberger R, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 2004; 28:914-920.
43. Kurt E, Zheng PP, Hop WC, et al. Identification of relevant prognostic histopathologic features in 89 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 2006; 106:388-395.
44. Merchant TE, Haida T, Wang MH, et al. Anaplastic ependymoma: treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg 1997; 86:943-949.
45. Schwartz TH, Kim S, Glick RS, et al. Supratentorial ependymomas in adult patients. Neurosurgery 1999; 44:721-731.
46. Metellus P, Figarella-Branger D, Guyotat J, et al. Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 2008; 113.175-185. A multiinstitutional retrospective analysis of outcome of adult supratentorial ependymomas.
47. Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991; 28:666-671.
48. Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 2002; 25:117-122.
49. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005; 102:629-636.
50. Rezai AR, Woo HH, Lee M, et al. Disseminated ependymomas of the central nervous system. J Neurosurg 1996; 85:618-624.
51. Van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002; 97:827-835.
52. Good CD, Wade AM, Hayward RD, et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? J Neurosurg 2001; 94:27-32.
53. Garrett PG, Simpson WJ. Ependymomas: results of radiation treatment. Int J Radiat Oncol Biol Phys 1983; 9:1121-1124.
54. Taylor RE. Review of radiotherapy dose and volume for intracranial ependy-moma. Pediatr Blood Cancer 2004; 42:457-460.
55. Wallner KE, Wara WM, Sheline GE, et al. Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. Int J Radiat Oncol Biol Phys 1986; 12:1937-1941.
56. Vanuytsel L, Brada M. The role of prophylactic spinal cord irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991; 21:825-830.
57. Vanuytsel L, Bessell EM, Ashley SE, et al. Intracranial ependymoma: long term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23:313-319.
58. Schild SE, Nisi K, Scheithauer BW, et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998; 42:953-958.
59. Timmermann B1 Kortmann RD, Kuhl J, et al. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000; 46:287-295.
60. Paulino AC. The local field in infratentorial ependymoma: does the entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys 2001; 49:757-761.
61. Donahue B, Steinfeld A. Intracranial ependymoma in the adult patient: successful treatment with surgery and radiotherapy. J Neurooncol 1998; 37:131-133.
62. Mork SJ, Loken AC. Ependymoma: a follow-up study of 101 cases. Cancer 1977; 40:907-915.
63. Salazar OM, Castro-Vita H, VanHoutte P, et al. Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 1983; 59:652-659.
64. Shaw EG, Evans RG, Scheithauer BW, et al. Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 1987; 13:1457-1462.
65. Awaad YM, Allen JC, Miller DC, et al. Deferring adjuvant therapy for totally resected intracranial ependymoma. Pediatr Neurol 1996; 14:216-219.
66. Hukin J, Epstein F, Letton D, et al. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998; 29:40-45.
67. Stafford SL, Pollock BE, Foots RL, et al. Stereotactic radiosurgery for recurrence ependymomas. Cancer 2000; 88:870-875.
68. Mansur DB, Drzymala RE, Rich KM, et al. The efficacy of stereotactic radiosurgery in the management of intracranial ependymoma. J Neurooncol 2004; 66:187-190.
69. Combs SE, Thilmann C, Debus J, et al. Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT). BMC Cancer 2006; 6:222.
70. Lo SS, Abdulrahman R, Desrosiers PM, et al. The role of Gamma Knife Radiosurgery in the management of unresectable gross disease or gross residual disease after surgery in ependymoma. J Neurooncol 2006; 79:51-56.
71. Gornet MK, Buckner JC, et al. Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999; 45:61-67.
72. Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo ltaliano Cooperativo di Neuro-Oncologia. Cancer 2005; 104:143-148.
73. Rojas-Marcos I, Calvet D, Janoray P, et al. Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology 2003; 61:1019-1020.
74. Malkin MG. Chemotherapy of ependymoma. In: Newton HB, editor. Handbook of brain tumor chemotherapy. London: Academic Press, Elsevier; 2006 pp. 426-431.
75. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55:2853-2857.
76. Rehman S, Brock C, Newlands ES. A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol 2006; 29:106-107.
77. Rudà R, Costanza A, Nobile M, et al. Response of ependymomas to chemotherapy with temozolomide. J Neurooncol 2001; 3:66.
78. Peschel RE, Kapp DS, Cardinale F, et al. Ependymomas of the spinal cord. Int J Radiat Oncol Biol Phys 1983; 9:1093-1096.
79. Whitaker SJ, Bessell EM, Ashley SE, et al. Postoperative radiotherapy in the management of spinal cord ependymoma. J Neurosurg 1991; 74:720-728.
80. Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol 2006; 80:177-183.
81. Dickerman RD, Reynolds AS, Gilbert E, et al. The importance of early postoperative radiation in spinal myxopapillary ependymomas. J Neurooncol 2007; 82:323-325. The first report of a CSF spread of a myxopapillary spinal ependymoma as early as six weeks after surgery.
82. Graf M, Blaeker H, Otto HF. Extraneural metastasizing ependymoma of the spinal cord. Pathol Oncol Res 1999; 5:56-60.
83. Gomez DR, Missett BT, Wara WM, et al. High failure rate in spinal ependymomas with long-term follow-up. Neuro Oncol 2005; 7:254-259.
84. Abdel-Wahab M, Etuk B, Palermo J, et al. Spinal cord gliomas: a multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys 2006; 64:1060-1071.
85. Marks JE, Adler SJ. A comparative study of ependymomas by site of origin. Int J Radiat Oncol Biol Phys 1982; 8:37-43.
86. Wen BC, Hussey DH, Hitchon PW, et al. The role of radiation therapy in the management of ependymomas of the spinal cord. Int J Radiat Oncol Biol Phys 1991;20:781-786.
87. Guidetti B, Mercuri S, Vagnozzi R. Long-term results of the surgical treatment of 129 intramedullary spinal gliomas. J Neurosurg 1981; 54:323-330.
88. Cooper PR, Epstein F. Radical resection of intramedullary spinal cord tumors in adults. Recent experience in 29 patients. J Neurosurg 1985; 63:492-499.
89. McCormick PC, Torres R, Post KD, et al. Intramedullary ependymoma of the spinal cord. J Neurosurg 1990; 72:523-532.
90. Volpp PB, Han K, Kagan AR, et al. Outcomes in treatment for intradural spinal cord ependymomas. Int J Radiat Oncol Biol Phys 2007; 69:1199-1204. A retrospective study confirming the value of en-bloc gross total resection as initial treatment for spinal cord ependymomas.
91. Hanbali F, Fourney DR, Marmor E, et al. Spinal cord ependymoma: radical surgical resection and outcome. Neurosurgery 2002; 51:1162-1172.
92. Lin YH, Huang CI, Wong TT, et al. Treatment of spinal cord ependymomas by surgery with or without postoperative radiotherapy. J Neurooncol 2005; 71:205-210.
93. Schwartz TH, McGormick PC. Intramedullary ependymomas: clinical presentation, surgical treatment strategies and prognosis. J Neurooncol 2000; 47:211-218.
94. Cooper PR. Outcome after operative treatment of intramedullary spinal cord tumors in adults: intermediate and long-term results in 51 patients. Neurosurgery 1989; 25:855-859.
95. Garcia DM. Primary spinal cord tumors treated with surgery and postoperative irradiation. Int J Radiat Oncol Biol Phys 1985; 11:1933-1939.
96. Linstadt DE, Wara WM, Leibel SA, et al. Postoperative radiotherapy of primary spinal cord tumors. Int J Radiat Oncol Biol Phys 1989; 16:1397-1403.
97. Waldron JN, Laperriere NJ, Jaakkimainen L, et al. Spinal cord ependymomas: a retrospective analysis of 59 cases. Int J Radiat Oncol Biol Phys 1993; 27:223-229.
98. Sgouros S, Malluci CL, Jackowski A. Spinal ependymomas: the value of postoperative radiotherapy for residual disease control. Br J Neurosurg 1996; 10:559-566.
99. Wahab SH, Simpson JR, Michalski JM, et al. Long term outcome with postoperative radiation therapy for spinal canal ependymoma. J Neurooncol 2007; 83:85-89. A retrospective study evaluating the long term efficacy and safety of postoperative radiation therapy in the managment of spinal canal ependymoma.
100. Shaw EG, Evans RG, Scheithauer BW, et al. Radiotherapeutic management of adult intraspinal ependymomas. Int J Radiat Oncol Biol Phys 1986; 12:323-327.
101. Wara WM, Sheline GE. Radiation therapy of malignant brain tumors. Clin Neurosurg 1978; 25:397-402.
102. Schultheiss TE, Stephens LC, Peters U. Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys 1986; 12:1765-1769.
103. van der Kogel AJ. Retreatment tolerance of the spinal cord. Int J Radiat Oncol Biol Phys 1993; 26:715-717.
104. Begemann M, De Angelis LM. Chemotherapeutic treatment of ependymomas ar Memorial Sloan-Kettering Cancer Center from 1994 to 2000. Proc Am Soc Clin Oncol 2001; 20:65a-258a.
105. Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymona. Cancer 2002; 95:997-1002.
106. Fakhrai N, Neophytou P, Dieckmann K, et al. Recurrent spinal ependymoma showing partial remission under imatimib. Acta Neurochir 2004; 146:1255-1258.